Investor profile
Panacea Capital
See how your deck fits this investor's thesis, stage, and ticket size.
Analyse your fitInvestment thesis
Panacea Capital is a life sciences venture fund with global vision and reach, spun out from Kleiner Perkins, dedicated to transforming lives through promising innovation. The firm specializes in investing and incubating early- and growth-stage life sciences companies with breakthrough technologies and discoveries that address unmet medical needs, focusing on biotech/pharma, medical devices/diagnostics, and healthcare IT and services across China, the U.S., Europe, and other major global life sciences hubs. Panacea builds and captures value from company formation through expansion stage to public market investing, deploying an asset-centric strategy with creative, adaptive investment structures. The firm invests across the full company lifecycle — from early-stage innovation to later-stage growth opportunities — participating in both private and public markets, with a team of 19+ partners and venture partners bringing more than 100 years of combined investing experience.
Notable quotes
“Panacea is grateful for the continued support of our existing and new limited partners in the growth of our platform. We will work hard to continue delivering attractive risk-adjusted returns driven by rigorous investment process and a highly experienced team in the global healthcare sector.”
“If you have both scientific and business model innovation, your probability of success is much, much higher.”
“Not all investors are alike. Very early on, you need to be able to differentiate those who can really help you on the journey from those who are trying to make a quick buck.”
Recent investments
| Company | Round | Size | Date |
|---|---|---|---|
| Kainova Therapeutics | Series B | $24m | 2026-02-10 |
| Myrtelle | Series B | $31m | 2025-12-23 |
| OutSee | Seed | $2m | 2025-06-24 |
| Actym Therapeutics | Series A | $60m | 2023-06-01 |
| Kindstar Global | Growth | — | — |
| Zhaoke Ophthalmology | Growth | — | — |
| Juventas Therapeutics | Series A | — | — |
| GT Apeiron Therapeutics | Seed | — | — |
| BioFront Therapeutics | Seed | — | — |
| Human Longevity | Growth | — | — |
Frequent co-investors
Fit check
Is Panacea Capital a match for your startup?
Upload your deck and get an instant AI-powered fit analysis — see exactly how your startup aligns with this investor's thesis, stage focus, and ticket size.
Analyse your fit